Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Research & Development: 2023-2025

Historic Research & Development for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $36.7 million.

  • Monte Rosa Therapeutics' Research & Development rose 32.81% to $36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.4 million, marking a year-over-year increase of 26.00%. This contributed to the annual value of $121.6 million for FY2024, which is 9.25% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Research & Development stood at $36.7 million, which was up 19.66% from $30.7 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Research & Development high stood at $38.9 million for Q4 2024, and its period low was $26.8 million during Q1 2023.
  • For the 3-year period, Monte Rosa Therapeutics' Research & Development averaged around $30.2 million, with its median value being $28.3 million (2023).
  • The largest annual percentage gain for Monte Rosa Therapeutics' Research & Development in the last 5 years was 43.23% (2024), contrasted with its biggest fall of 3.51% (2024).
  • Over the past 3 years, Monte Rosa Therapeutics' Research & Development (Quarterly) stood at $27.1 million in 2023, then soared by 43.23% to $38.9 million in 2024, then spiked by 32.81% to $36.7 million in 2025.
  • Its Research & Development stands at $36.7 million for Q3 2025, versus $30.7 million for Q2 2025 and $32.2 million for Q1 2025.